Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628639 | 1.00 | DRD2 (0.34) | DRD2DRD4DRD3FFAR1POLB | |
| SCHEMBL6676539 | 0.80 | LMNA (0.38) | FFAR1POLBHPGD | |
| SCHEMBL6674662 | 0.80 | LMNA (0.38) | FFAR1POLBHPGD | |
| SCHEMBL8192039 | 0.79 | HTR1A (0.46) | FFAR1POLBHPGDTDP1L3MBTL1 | |
| SCHEMBL8855833 | 0.74 | SIRT1 (0.34) | — | |
| SCHEMBL8976461 | 0.72 | ADRA1D (0.42) | POLBHPGDTDP1L3MBTL1HTR1A | |
| SCHEMBL4523570 | 0.71 | TXNRD1 (0.36) | KMT2ATDP1L3MBTL1 | |
| SCHEMBL4361272 | 0.71 | TXNRD1 (0.36) | KMT2ATDP1L3MBTL1 | |
| SCHEMBL7083540 | 0.70 | GABRA1 (0.37) | DRD3HTR1ASLC6A2 | |
| SCHEMBL7083543 | 0.70 | GABRA1 (0.37) | DRD3HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485384-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | Pharmacia & Upjohn Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1381613-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED-(1,4)-BENZODIOXANS | WYETH CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6706736-B2 | AMINES SUCH AS 3-(1-((8-METHYL-2,3-DIHYDROFURO(2,3-F)(1,4) BENZODIOXIN-2-YL)METHYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE, ADMINISTERED AS SEROTONIN REUPTAKE INHIBITORS OR ANXIOLYTIC AGENTS | WYETH | 2004-03-16 | — | — | US | disclosed |
| WO-2003078435-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2003-08-28 | — | — | US | disclosed |
| US-6552049-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-04-22 | — | — | US | disclosed |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | DRD2 10/4885DRD4 22/4885DRD3 19/4885 |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | DRD2 17/4885DRD4 35/4885DRD3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.